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Abstract
Background: Little is known about the factors influencing treatment choice in psychosis, the majority of this work
being conducted with specialists (consultant) in psychiatry. We sought to examine trainees’ choices of treatment
for psychosis if they had to prescribe it for themselves, their patients, and factors influencing decision-making.
Methods: Cross-sectional, semi-structured questionnaire-based study.
Results: Of the 726 respondents (response rate = 66%), the majority chose second-generation antipsychotics
(SGAs) if they had to prescribe it for themselves (n = 530, 93%) or for their patients (n = 546, 94%). The main factor
influencing choice was perceived efficacy, 84.8% (n = 475) of trainees stating this was the most important factor
for the patient, and 77.8% (n = 404) stating this was the most important factor for their own treatment. Trainees
with knowledge of trials questioning use of SGAs (CATIE, CUtLASS, TEOSS) were more likely to choose second-
generation antipsychotics than those without knowledge of these trials (c2 = 3.943; p = 0.047; O.R. = 2.11; 95% C.I.
= 1.0-4.48). Regarding psychotherapy, cognitive behavioural therapy (CBT) was the most popular choice for self
(33.1%; n = 240) and patient (30.9%; n = 224). Trainees were significantly more likely to prefer some form of
psychotherapy for themselves rather than patients (c2 = 9.98; p < 0,002; O.R. = 1.54; 95% CIs = 1.18-2.0).
Conclusions: Trainees are more likely to choose second-generation antipsychotic medication for patients and
themselves. Despite being aware of evidence that suggests otherwise, they predominantly base these choices on
perceived efficacy.
Keywords: Antipsychotics, Drug therapy, Psychiatry trainees, Evidence-based medicine, Decision-making, Efficacy,
Psychotherapy, Psychosis, Treatment
Background
Historically, treatments in psychiatry have invariably
been controversial, from the days of insulin coma and
leucotomy to the use of psychotropic medication in the
modern era. Recently the spotlight has fallen on use of
antipsychotics (or more accurately, the choice of antipsy-
chotic medication) for the treatment of psychosis.
The inception of Chlorpromazine, in 1950, signified a
paradigm shift in the management (and our understand-
ing) of schizophrenia. Although several other antipsy-
chotics were developed over the following years, it took
till the 1980s for clear evidence of benefit for one speci-
fic antipsychotic (Clozapine) to emerge [1]. Subse-
quently, another class of antipsychotics, the (so-called)
“atypical” antipsychotics (or second-generation antipsy-
chotics (SGA)) were developed. At the time of their
introduction these drugs were promoted as having
superior efficacy and better side-effect profiles to their
older counterparts [2]. This came at a price: these drugs
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were initially priced much higher than their older coun-
terparts, though, guidelines continued to recommend
their use [3].
However, following the publication of at least two
recent large effectiveness trials [4,5], these assump-
tions have been significantly challenged. Moreover,
the effectiveness of SGAs (with the exception of Clo-
zapine) has been shown to be roughly equivalent to
their first-generation counterparts, with differing side-
effect profiles, with one recent trial being discontin-
ued on account of metabolic side-effects observed
with one of the SGAs [6].
Despite this evidence, it is difficult to tell how any of
the recent notions of efficacy and tolerability of SGAs
have impacted on clinical practice, and if this has influ-
enced actual clinical decision-making. In contrast to the
burgeoning literature on antipsychotics, relatively few
studies have examined decision-making in the context
of psychosis. Methods used for this include semi-struc-
tured interviews with psychiatrists, and preference for
psychiatrists’ own treatment [7-9]. The majority of this
work has been conducted locally (in one case a national
survey), predominantly with psychiatry consultants/spe-
cialists. To date, there has been little work examining
trainee psychiatrists’ views on treatment, and no exami-
nation of their views on psychotherapy. Moreover,
populations that have been looked at have only included
those from the United Kingdom and Germany [8-10].
Thus, further work is warranted.
The aim of this study was to ascertain choices of psy-
chiatric trainees from various European countries
regarding antipsychotic treatments, the factors influen-
cing their choices, and whether treatment choices were
altered when trainees were asked which treatment they
would choose for their own care.
Methods
Study participants
Participants were given a guarantee that every attempt
would be made to ensure that responses to the ques-
tionnaire would be confidential. In view of these condi-
tions, returning a pseudo-anonymised questionnaire was
considered to be indicative of informed consent. These
considerations are in keeping with the ethical principles
set out in the Declaration of Helsinki [11].
Inclusion criteria
To ensure adequate reliability, a minimum sample of 50
trainees from each country was agreed on. Each country
participant was asked to sample a group of trainees that
included trainees from a similar institution or area, and
this represented an opportunistic sample. A minimum
response rate for inclusion into the study was set (50%).
Survey
Based on guidelines for surveys [12] and prior work
[9,10] that utilised semi-structured questionnaires asking
about choice for oneself, patients and factors influencing
choice, an ad hoc semi-structured survey was developed.
This survey was piloted with psychiatric trainees attend-
ing the EFPT (European Federation of Psychiatric Trai-
nees) Annual Forum. The survey was distributed in
English, via a web-link and via paper copy, for six
months, between October 2008 and March 2009. During
this period, country representatives were regularly
updated on response rates to the web survey, and were
permitted to contact participants. The full survey is
given in Additional file 1: Appendix 1, and included
i) Demographic details (gender, country, adult or
child and adolescent trainee, years of training).
ii) Antipsychotic choice for patients presenting with
a psychotic episode lasting longer than one month
(typical, atypical).
iii) Generic drug name for antipsychotic chosen.
iv) Factors influencing choice (cost, efficacy, side
effect profile, other).
v) Whether any recent trials had influenced deci-
sion-making (given choice of CATIE, CUtLASS,
TEOSS or other). These trials were chosen on
account of their topical nature, large numbers and
perceived influence.
vi) Whether adjunctive psychotherapy would be con-
sidered (and reasons for doing so).
vii) Trainees’ choice of antipsychotic if they devel-
oped a psychotic episode lasting one month or
longer (class, generic drug) and factors influencing
choice, and adjunctive psychotherapy.
Through the web forum, agreement was reached on
operational definitions (and understanding) of the terms
“antipsychotic”, “typical antipsychotic”, “atypical antipsy-
chotic” and “psychotic episode”.
Analysis
Output from the web-survey tool was analysed using
Predictive Analytics Software Statistics Programme
(PASW; version 18.0). Given the exploratory nature of
our analysis, chi-square tests, or Fisher’s exact tests
when relevant, were used to compare categorical data.
Statistical significance was set at p < 0.05. The qualita-
tive responses on choice of psychological treatments
were analysed using content analysis, with comparisons
being made between the reasons for the treatment cho-
sen, according to set criteria. This was performed sepa-
rately by SG, and SJ and NM, and the results were
compared and revised to increase reliability.
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Results
Of the 18 countries originally participating in the survey,
only 12 met inclusion criteria listed above. Countries
that participated but were not included were Croatia,
Germany, Italy, Russia, Spain and Sweden. These coun-
tries were excluded on account of being unable to col-
lect samples meeting the inclusion criteria. Reasons for
this included “research fatigue” (a number of other sur-
veys were being conducted at the current time).
The included countries and response rates are given in
Table 1.
Demographic characteristics
Of the 726 trainees, 84.4% (n = 613) were adult psychia-
try trainees and 15% (n = 109) were child and adoles-
cent psychiatry trainees. 54.8% (n = 398) of the sample
were females. The mean duration of completed training
was 2.97 (s.d. = 1.57) years. More than half of the trai-
nees were in the first half of their training (n = 438;
60%).
Oral antipsychotic choice
Antipsychotic choice for patients and trainees them-
selves, grouped by class and generic name, are presented
in Table 2. Given recent evidence, underlining that the
“atypical” and “typical” antipsychotics are heterogeneous
entities [13], and that some atypical antipsychotics may
have more efficacy than others, we examined choices of
specific antipsychotics. Regarding the class of antipsy-
chotic (atypical, typical or no antipsychotic), there were
no differences between trainees’ treatment choices for
their patients or for themselves (Figure 1).
Olanzapine was the most popular choice for the
patient in the scenario, and Risperidone the most
popular choice for trainees themselves (Figure 2). Trai-
nees were more likely to prescribe olanzapine for
patients (c2 = 16.83, p < 0.0001, O.R. = 1.9, 95% C.I. =
1.38-2.53), and aripiprazole for themselves (c2 = 24.48, p
< 0.001, O.R. = 3.2, 95% C.I. = 2.0-5.2). Only one typical
antipsychotic drug (haloperidol) was chosen. Forty-five
(6%) trainees did not choose a generic antipsychotic,
stating that the decision would depend on characteris-
tics of the patient and their symptom profile (e.g., need
for sedation and side-effects experienced). No difference
was seen between males and females for antipsychotic
choice for patient or self.
Differences between countries
Differences between countries and antipsychotic choice
were examined, using chi-square tests. Trainees from
Holland were more likely to prescribe typical antipsy-
chotics for patients than those from other countries, (c2
= 16.18; p = 0.01; O.R. = 4.76; 95% C.I. = 2.08-10.86).
Dutch trainees were also more likely to choose typical
antipsychotics for their own treatment, compared to
trainees from other countries, (c2 = 51.6; p < 0.001; O.
R. = 10.9; 95% C.I. = 5-23.8). A similar finding was
found with trainees from Turkey, in regard to treatment
for the patient in the given scenario, (c2 = 32.35; p <
0.001; O.R. = 6.90; 95% C.I. = 3.26-14.7).
Antipsychotic class
528 trainees filled in both questions “antipsychotics for
self” and “antipsychotics for patients”. Trainees were no
more likely to prescribe an atypical for themselves
(93.6%) than they would for patients (94.5%) (c2 = 0.42;
p = 0.5, OR = 0.84 (95% C.I. = 0.5-1.4). As detailed
above there were multiple entries for specific
Table 1 Countries meeting inclusion criteria and response rates
Country Number of participants/Total number sampled Response rate (%)
Belgium 52/104 50%
Czech Republic 60/92 65%
England 53/98 54%
France 60/100 60%
Greece 75/100 75%
Holland 54/75 72%
Ireland 51/72 71%
Portugal 52/94 40-55%1
Romania 74/99 75%
Scotland 54/75 72%
Switzerland 83/124 67%
Turkey 58/70 83%
Total 726/1103 66%
(Countries that participated but were not included were Croatia, Germany, Italy, Russia, Spain and Sweden). 1Estimated response rate, based on variable reliability
of email addresses
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antipsychotics, and therefore it was not possible to
include these in the calculation of odds ratios, as those
who selected two antipsychotics did not consider one to
be superior to the other.
Factors influencing choice of antipsychotic
Factors influencing choice mapped onto the three main
domains given in the questionnaire: cost, efficacy and
side-effect profile. Less than 5% of trainees gave other
reasons. Results are summarised in Table 3. Efficacy was
the most important factor influencing choice for treating
patients as well as for oneself, followed by side effect
profile and then cost. When considering their own treat-
ment (as opposed to a patient), trainees were signifi-
cantly more inclined to think of side-effect profile (c2 =
15.49; p < 0.0001; O.R. = 1.64; 95% C.I. = 1.28-2.10),
and less inclined to think of efficacy (c2 = 8.69; p =
0.03; O.R. = 0.63; 95% C.I. = 0.46-0.86). Factors influen-
cing specific antipsychotic choice are summarized in
Table 4. Trainees favoured efficacy over side-effect pro-
file for all drugs, except Aripiprazole for patients and
themselves, and Quetiapine for themselves. For these
Table 2 Antipsychotics chosen by trainee in given scenario and for own care
Antipsychotic chosen Physician’s choice for patient Physician’s choice if they developed psychosis
Atypical 546 (94%) 530 (93%)
Typical 35 (6%) 40 (7%)
No antipsychotic 4 (0.7%) 0
Olanzapine 167 (210) 39.9% 100 (120), 26.2%
Risperidone 154 (202) 36.8% 123 (141), 32.3%
Haloperidol 28 (33) 6.7% 21 (23), 5.5%
Aripiprazole 25 (33) 6% 65 (73) 17%
Amisulpiride 17 (21) 4.1% 19 (24) 5%
Quetiapine 22 (36) 5.3% 25 (37) 6.6%
Clozapine 6 (8) 1.4% 22 (24) 5.8%
No response given regarding generic drug 202 304
Electroconvulsive therapy (ECT) 0 1 0.3%
Ziprasidone 0 4 1%
Sertindole 0 1 0.3%
Percentages given are of those who responded to the question. Some respondents chose one or more antipsychotics concurrently; numbers in brackets include
these additions. The table illustrates that the “atypical” class of antipsychotics were the most popular choice for patients and trainees themselves
Figure 1 Type of antipsychotic chosen by trainees, for patients or for trainees themselves.
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two drugs, side-effect profile was the most important
criterion.
Prior knowledge of effectiveness trials
The percentage of trainees who reported that prior
knowledge of effectiveness trials (CATIE, CUtLASS and
TEOSS) had influenced their antipsychotic choice was
33.8% (n = 246), 8.1% (n = 59) and 1.5% (n = 11),
respectively. Trainees with prior knowledge of at least
one effectiveness trial chose atypical antipsychotics for
the patient in the scenario more than trainees with no
prior knowledge of any of these effectiveness trials
(96.1% versus 92.3%; c2 = 3.943; p = 0.047; O.R. = 2.11;
95% C.I. = 1.0-4.48).
Influence of trainee seniority and type of trainee
No differences in class of antipsychotic chosen for
patients were seen between trainees in the first and sec-
ond halves of training (92.3% versus 95.3%; c2 = 2.12; p
= 0.15; O.R. = 1.70; 95% C.I. = 0.83-3.3.40), and no sta-
tistically significant difference was observed between
child and adolescent psychiatry trainees and adult trai-
nees (97.4% versus 93.4%; Fisher exact p = 0.13).
Choice of adjunctive psychotherapy
Choices of psychotherapy for both the patient in the
scenario and for oneself are given in Table 5. Cognitive
behavioural therapy (CBT) was the most popular choice
for self and patient. Trainees were significantly more
likely to prefer some form of psychotherapy for them-
selves rather than patients (c2 = 9.98; p < 0,002; O.R. =
1.54; 95% C.I. = 1.18-2.0). Psychodynamic psychotherapy
was chosen more by trainees for themselves than for the
patient in the scenario (c2 = 15.53; p < 0.001; O.R. =
2.63; 95% C.I. = 1.6-4.3).
Qualitative analysis of psychotherapy
289 trainees gave qualitative responses. There was no
difference in the qualitative responses between psy-
chotherapy treatments chosen by trainees for themselves
or for their patients. The factors influencing a trainee
not to use psychotherapy included a lack of evidence
base/guidelines (n = 6), clinical experience (n = 9), lack
Figure 2 Percentages of drug chosen by trainees, for patients or for trainees themselves.
Table 3 Factors influencing choice of antipsychotic for
patient/self
Efficacy Side-effect
profile
Cost
Patient Self Patient Self Patient Self
Most important 475
(84.8%)
404
(77.8%)
191
(34.5%)
237
(46.4%)
17
(3.2%)
13
(2.7%)
2nd most
important
84
(15%)
115
(22.2%)
326
(59%)
258
(50.1%)
91
(17.2%)
69
(14.2%)
Least important 1
(0.2%)
0 36
(6.5%)
16
(3.1%)
422
(79.6%)
405
(83.2%)
Respondents could choose more than one factor at each stage of importance;
percentages reported are for those responding to the question
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of access to the treatment (n = 2), the opinions and
practice of senior psychiatrists (n = 2) and the fact that
the patient may be too unwell (n = 3). Many trainees
described the usefulness of using unstructured forms of
therapy such as supportive psychotherapy and of waiting
until the psychotic symptoms had settled before consid-
ering therapy. Factors influencing choice of CBT
included evidence base/guidelines (n = 63), availability
(n = 2), low cost (n = 3), structured and less intensive
approach (n = 2). Reasons for interpersonal therapy
included allowing patients to cope (n = 3). Their clinical
experience of using mindfulness-based treatment (n = 3)
was used as a reason for its use.
Those favouring psychodynamic psychotherapy did so
mostly because that was the treatment they were trained
in (n = 6), with little mention of its evidence base (n = 2).
As some trainees were already receiving psychodynamic
psychotherapy they stated they would want this to con-
tinue if they developed a psychotic episode (n = 11).
Discussion
Pharmacotherapy
Our results suggest trainees prefer to prescribe, and
receive SGAs, based on assumptions of improved effi-
cacy and side-effect profile. These assumptions have
been challenged by recent evidence [13]. What is strik-
ing is that, despite knowledge of recent evidence (trials
that suggest small difference between classes), trainees
would not change their prescribing practice. Although
they would broadly choose the same class of
antipsychotic for patients and themselves, some would
wish to be treated with differing antipsychotics to their
patients, basing this decision on side-effect profile.
There was a general trend for more emphasis on side-
effect profiles when the treatment was prescribed for
trainees themselves.
The results regarding antipsychotics are similar to
those of other studies, conducted in England, Germany
and Scotland [8-10]. In all the previous studies “atypical”
antipsychotics were preferred, with olanzapine and ris-
peridone the most popular choices.
Factors influencing choice are generally similar to
those reported elsewhere, with efficacy and side-effect
profile/tolerability viewed as most important [8,9], a nat-
uralistic study finding that physicians were more likely
to base antipsychotic choice in clinical practice on side-
effects [14]. This was reflected in our sample, when trai-
nees chose their medication they would prefer to receive
(significantly less choosing olanzapine and significantly
more choosing aripiprazole), a possible reason for this
being the difference in side-effects between these com-
pounds, though this was not examined in further detail.
Decision-making was also examined in face to face
interviews with German psychiatrists, the only distin-
guishing factor amongst participants being age, with
older doctors being more likely to prescribe typical anti-
psychotics [7]. This was not found in our study, though
we would suggest trainees with more experience have
no significant exposure to the older compounds, unlike
those in the German study.
Table 4 Factors influencing the choice of a specific antipsychotic for patient/self
Olanzapine Risperidone Haloperidol Quetiapine Aripiprazole Amisulpiride Clozapine
P S P S P S P S P S P S P S
Efficacy
most
important
155
(92.8%)
93
(93%)
129
(83.8%)
118
(76.1%)
23
(82.1%)
15
(78.9%)
16
(72.7%)
14
(56%)
10
(40%)
32
(49.2%)
16
(94.1%)
16
(84.2%)
6
(100%)
20
(90.9%)
Side effect
profile most
important
38
(22.8%)
25
(25%)
39
(25.3%)
70
(45.2%)
6
(21.4%)
6
(31.6%)
13
(59.1%)
19
(76%)
16
(64%)
44
(67.7%)
4
(23.5%)
7
(36.8%)
0 3
(13.6%)
P refers to patient; S refers to self
(Note: some trainees chose more than one factor at a time)
Table 5 Choice of psychotherapy for patient/self
Treatment for patient Treatment for self
None 187 (25.8%) 133 (18.7%)
Any kind of psychotherapy 331 362**
Cognitive Behavioural Therapy (CBT) 240 (33.1%) 224 (30.9%)
Interpersonal Therapy 50 (6.9%) 56 (7.7%)
Mindfulness-based Therapy 17 (2.3%) 26 (3.5%
Psychodynamic Psychotherapy 24 (3.3%) 56 (7.7%)***
Not responded 208 (28.7%) 231 (31.8%)
**: p < 0.01; ***: p < 0.001
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Psychotherapy
Findings regarding psychotherapy are that trainees chose
to receive therapy for themselves more often than for
patients, and that this was based on personal experience.
CBT was the most popular choice, and evidence base
was cited as the reason for this. A number of trainees
who had received psychodynamic therapy for themselves
wanted to receive this if they developed psychosis.
Though did not choose this for the patient in the given
scenario.
“Evidence-based medicine”
The finding in regard to knowledge of effectiveness
trials is counter-intuitive, and may reflect concerns trai-
nees may have had with the trials themselves, and their
interpretation of the results, owing to methodological
issues, that have been highlighted elsewhere [15]. It may
also reflect wider concerns, regarding the philosophical
underpinnings of EBM itself, which have been elo-
quently argued elsewhere [16]. Briefly, this consists of
theoretical constructs (EBM) versus clinical observation.
This probably has relevance to our sample, as a number
of trainees stated that both clinical experience and evi-
dence had affected their choice of psychotherapy.
To our knowledge this is the only study that has
examined choice of psychotherapy in psychosis, none of
the above studies examining this question. This area is
worth examining, especially in the context of recent lit-
erature that questions efficacy of CBT in psychosis,
querying if any benefit is seen in well-conducted studies
[17], and recent guidelines that advocate for its use.
The finding that physicians would have differing pre-
ferences for their own care has been examined in detail
in a recent German study of 515 psychiatrists, who were
randomised to various groups [18]. In that study, when
given a scenario involving a patient with a relapse of
psychosis in schizophrenia, physicians chose watchful
waiting and oral antipsychotic medication, as opposed
to depot antipsychotic medication when asked about
treatment for a patient, or themselves.
Weaknesses of this study pertain to its design (cross
sectional, arbitrary survey with an opportunistic sample),
which lacks the thoroughness and validity of a face-to-
face interview. The results from all the countries were
pooled, but we have to keep in mind that the training
systems, health systems, and the availability of the
drugs, are different between the different countries.
Although efforts were made to recruit an adequate sam-
ple that was felt to be representative, the fact that only a
small proportion of the total trainees in Europe were
surveyed tempers the generalisability of these results.
Furthermore, the validity of a sample of 50 in a country
like Portugal would be greater than those for a country
like England, which has significantly more trainees.
We would point out, however, that this is, to our
knowledge, the largest study conducted examining
choice, and the only one involving exclusively psychia-
tric trainees. This is relevant since most psychiatry trai-
nees have had more exposure to the second-generation
antipsychotics [19], and have less clinical experience to
base their decisions on. Moreover, psychiatric trainees
are tomorrow’s psychiatrists, and therefore these results
give us an overview of what future European prescrip-
tion patterns might be. We were also in a favorable
position to ask about changes in the recent evidence-
base, owing to the close proximity of the questionnaire
to the findings from effectiveness trials like CATIE.
Conclusions
European psychiatry trainees appear to base treatment
decisions on factors other than purely evidence-base,
and would choose similar treatments for psychosis (aty-
pical antipsychotics) for themselves and their patients.
Differences appear to exist in the individual compounds
they would choose to receive for themselves, possibly
reflecting concerns about side-effects, such as weight
gain. Future work would focus on what influences per-
ceptions of efficacy and side effect profile, and what role
the pharmaceutical industry and opinion leaders may
play in these assumptions.
Additional material
Additional file 1: Appendix 1.
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